TuHURA Biosciences, Inc.(HURA)

Biotechnology · Tampa, FL

$1.97+0.10 (+5.35%)

Delayed quote: Oct 6, 2026, 3:14 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T19:17:05.400Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:17:05.400Z.

Quote observation: 2026-10-06T19:14:34.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 125,454,527
Total debt · period ending 2026-06-30: 407,023
Cash · period ending 2026-06-30: 995,977
TTM operating EBITDA · period ending 2026-06-30: -31,100,731

FMP input reference: 521b0ab3da901f2a49dafbbedcb3688a082548b97bbb2cd5efdb729e6989e7c5

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

HURA EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

HURA Competitors' EV/EBITDA Ratio

HURA

TuHURA Biosciences, Inc.

Current

Market Cap

$125.45M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TNXP

Tonix Pharmaceuticals Holding Corp.

vs HURA

Market Cap

$125.09M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENTX

Entera Bio Ltd.

vs HURA

Market Cap

$126.18M

EV/EBITDA Ratio

N/A

TTM Avg

3.93x

3Y Avg

3.93x

5Y Avg

3.93x

NRXP

NRx Pharmaceuticals, Inc.

vs HURA

Market Cap

$127.72M

EV/EBITDA Ratio

N/A

TTM Avg

3271.29x

3Y Avg

2827.81x

5Y Avg

2827.81x

CBUS

Cibus, Inc.

vs HURA

Market Cap

$120.99M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PYXS

Pyxis Oncology, Inc.

vs HURA

Market Cap

$128.40M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENGN

enGene Holdings Inc.

vs HURA

Market Cap

$120.92M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SEER

Seer, Inc.

vs HURA

Market Cap

$121.05M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TNYA

Tenaya Therapeutics, Inc.

vs HURA

Market Cap

$120.30M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LENZ

LENZ Therapeutics, Inc.

vs HURA

Market Cap

$119.31M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
TuHURA Biosciences, Inc. (HURA)	$125.45M	N/A	N/A	N/A	N/A
Tonix Pharmaceuticals Holding Corp. (TNXP)vs ›	$125.09M	N/A	N/A	N/A	N/A
Entera Bio Ltd. (ENTX)vs ›	$126.18M	N/A	3.93x	3.93x	3.93x
NRx Pharmaceuticals, Inc. (NRXP)vs ›	$127.72M	N/A	3271.29x	2827.81x	2827.81x
Cibus, Inc. (CBUS)vs ›	$120.99M	N/A	N/A	N/A	N/A
Pyxis Oncology, Inc. (PYXS)vs ›	$128.40M	N/A	N/A	N/A	N/A
enGene Holdings Inc. (ENGN)vs ›	$120.92M	N/A	N/A	N/A	N/A
Seer, Inc. (SEER)vs ›	$121.05M	N/A	N/A	N/A	N/A
Tenaya Therapeutics, Inc. (TNYA)vs ›	$120.30M	N/A	N/A	N/A	N/A
LENZ Therapeutics, Inc. (LENZ)vs ›	$119.31M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics